SPTX (Seaport Therapeutics) Revenue: $ Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SPTX Seaport Therapeutics Inc SPTX
11 GF Score
Price $20.40
! 2 Warning Signs
View Full Analysis

What is Seaport Therapeutics Revenue?

Seaport Therapeutics SPTX +0.69% 11 Revenue is $ Mil as of Dec. 2025. GuruFocus rates SPTX with a GF Score™ of 11/100. The stock has 2 warning signs investors should review.

Seaport Therapeutics's revenue for the six months ended in Dec. 2025 was $0.00 Mil. Seaport Therapeutics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Dec. 2025. Seaport Therapeutics's Revenue per Share for the six months ended in Dec. 2025 was $0.00. Seaport Therapeutics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

Seaport Therapeutics  (NAS:SPTX) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Seaport Therapeutics Revenue Related Terms

Seaport Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Seaport Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Seaport Therapeutics Revenue Chart

Seaport Therapeutics Annual Data
Trend Dec24 Dec25
Revenue
0.00 0.00

Seaport Therapeutics Semi-Annual Data
Dec24 Dec25
Revenue 0.00 0.00

SPTX vs SVRA, DRTS, FBRX: Revenue Comparison

For the Biotechnology subindustry, Seaport Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seaport Therapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seaport Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Seaport Therapeutics's Revenue falls into.


SPTX
11GF Score
Seaport Therapeutics Inc SPTX
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Seaport Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $ Mil mean?
Seaport Therapeutics (SPTX) has a Revenue of $ Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Seaport Therapeutics and its competitors.
Is Seaport Therapeutics' Revenue too high?
Seaport Therapeutics' current Revenue is $ Mil. Overall, Seaport Therapeutics has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Seaport Therapeutics' Revenue compare to SVRA and DRTS?
Seaport Therapeutics' Revenue of $ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Seaport Therapeutics and its competitors. Seaport Therapeutics's current Revenue is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Seaport Therapeutics stock overvalued right now?
Seaport Therapeutics (SPTX) has a current Revenue of $ Mil. The current Revenue is $ Mil. Seaport Therapeutics' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Seaport Therapeutics (SPTX), the current Revenue is $ Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Seaport Therapeutics Business Description

Address 101 Seaport Boulevard, Floor 12, Boston, MA, USA, 02210
Seaport Therapeutics Inc is a clinical-stage therapeutics company. The company focuses on invention and development of new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. The company identified clinically validated mechanisms with established efficacy and safety profiles, historically limited by high first-pass metabolism, low bioavailability, and side effects. The company's pipeline products are based on Glyph, company's lymphatic-targeting prodrug technology is designed to bypass first-pass metabolism and thereby enhance a drug's oral bioavailability and reduce side effects.
11GF Score

Get the complete analysis for SPTX

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.40
Price